Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 194

1.

Recovery pattern of hypothalamo-pituitary-testicular axis in patients with macroprolactinomas after treatment with cabergoline.

Walia R, Bhansali A, Dutta P, Khandelwal N, Sialy R, Bhadada S.

Indian J Med Res. 2011 Sep;134:314-9.

2.

Microsurgical management of prolactinomas - clinical and hormonal outcome in a series of 172 cases.

Sinha S, Sharma BS, Mahapatra AK.

Neurol India. 2011 Jul-Aug;59(4):532-6. doi: 10.4103/0028-3886.84332.

3.

Gamma knife radiosurgery for patients with prolactin-secreting pituitary adenomas.

Tanaka S, Link MJ, Brown PD, Stafford SL, Young WF Jr, Pollock BE.

World Neurosurg. 2010 Jul;74(1):147-52. doi: 10.1016/j.wneu.2010.05.007.

PMID:
21300006
4.

Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline.

Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA; Endocrine Society.

J Clin Endocrinol Metab. 2011 Feb;96(2):273-88. doi: 10.1210/jc.2010-1692. Review.

PMID:
21296991
5.

Surgical outcomes and prognostic factors of transsphenoidal surgery for prolactinoma in men: a single-center experience with 87 consecutive cases.

Qu X, Wang M, Wang G, Han T, Mou C, Han L, Jiang M, Qu Y, Zhang M, Pang Q, Xu G.

Eur J Endocrinol. 2011 Apr;164(4):499-504. doi: 10.1530/EJE-10-0961. Epub 2011 Jan 20.

6.

Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis.

dos Santos Nunes V, El Dib R, Boguszewski CL, Nogueira CR.

Pituitary. 2011 Sep;14(3):259-65. doi: 10.1007/s11102-010-0290-z. Review.

PMID:
21221817
7.

Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists.

Babey M, Sahli R, Vajtai I, Andres RH, Seiler RW.

Pituitary. 2011 Sep;14(3):222-30. doi: 10.1007/s11102-010-0283-y.

8.

Clinical management and outcome of 36 invasive prolactinomas treated with dopamine agonist.

Yang MS, Hong JW, Lee SK, Lee EJ, Kim SH.

J Neurooncol. 2011 Aug;104(1):195-204. doi: 10.1007/s11060-010-0459-3. Epub 2010 Nov 24.

PMID:
21107645
9.

Treatment of pituitary adenomas using radiosurgery and radiotherapy: a single center experience and review of literature.

Sun DQ, Cheng JJ, Frazier JL, Batra S, Wand G, Kleinberg LR, Rigamonti D, Quinones-Hinojosa A, Salvatori R, Lim M.

Neurosurg Rev. 2010 Apr;34(2):181-9. doi: 10.1007/s10143-010-0285-2. Epub 2010 Sep 14.

PMID:
20838838
10.

Effectiveness of short-term maintenance treatment with cabergoline in microadenoma-related and idiopathic hyperprolactinemia.

Buyukbayrak EE, Karageyim Karsidag AY, Kars B, Balcik O, Pirimoglu M, Unal O, Turan C.

Arch Gynecol Obstet. 2010 Nov;282(5):561-6. doi: 10.1007/s00404-010-1562-6. Epub 2010 Jun 23.

PMID:
20571820
11.

Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia.

Tan T, Cabrita IZ, Hensman D, Grogono J, Dhillo WS, Baynes KC, Eliahoo J, Meeran K, Robinson S, Nihoyannopoulos P, Martin NM.

Clin Endocrinol (Oxf). 2010 Sep;73(3):369-74. doi: 10.1111/j.1365-2265.2010.03827.x. Epub 2010 Jun 9.

PMID:
20550538
12.

A comparison of bromocriptine & cabergoline on fertility outcome of hyperprolactinemic infertile women undergoing intrauterine insemination.

Motazedian S, Babakhani L, Fereshtehnejad SM, Mojthahedi K.

Indian J Med Res. 2010 May;131:670-4.

PMID:
20516539
13.

Comparison of cabergoline and bromocriptine in patients with asymptomatic incidental hyperprolactinemia undergoing ICSI-ET.

Bahceci M, Sismanoglu A, Ulug U.

Gynecol Endocrinol. 2010 Jul;26(7):505-8. doi: 10.3109/09513591003632233.

PMID:
20459348
14.

Efficacy of cabergoline on rapid escalation of dose in men with macroprolactinomas.

Bhansali A, Walia R, Dutta P, Khandelwal N, Sialy R, Bhadada S.

Indian J Med Res. 2010 Apr;131:530-5.

15.

Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.

Ono M, Miki N, Amano K, Kawamata T, Seki T, Makino R, Takano K, Izumi S, Okada Y, Hori T.

J Clin Endocrinol Metab. 2010 Jun;95(6):2672-9. doi: 10.1210/jc.2009-2605. Epub 2010 Mar 31.

PMID:
20357175
16.

Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia.

Valassi E, Klibanski A, Biller BM.

J Clin Endocrinol Metab. 2010 Mar;95(3):1025-33. doi: 10.1210/jc.2009-2095. Epub 2010 Feb 3. Review.

PMID:
20130078
17.

Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.

Lafeber M, Stades AM, Valk GD, Cramer MJ, Teding van Berkhout F, Zelissen PM.

Eur J Endocrinol. 2010 Apr;162(4):667-75. doi: 10.1530/EJE-09-0989. Epub 2010 Jan 13.

18.

Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis.

Dekkers OM, Lagro J, Burman P, Jørgensen JO, Romijn JA, Pereira AM.

J Clin Endocrinol Metab. 2010 Jan;95(1):43-51. doi: 10.1210/jc.2009-1238. Epub 2009 Oct 30. Review.

PMID:
19880787
19.

Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma.

Cho EH, Lee SA, Chung JY, Koh EH, Cho YH, Kim JH, Kim CJ, Kim MS.

J Korean Med Sci. 2009 Oct;24(5):874-8. doi: 10.3346/jkms.2009.24.5.874. Epub 2009 Sep 24.

20.

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group.

BMJ. 2009 Jul 21;339:b2535. doi: 10.1136/bmj.b2535. No abstract available.

Supplemental Content

Support Center